Meabco A/S is a Danish Biotech company based on a portfolio of novel therapeutic products within the field of cancer, invented by RDI, the main shareholder of Meabco.

Meabco A/S was established in 2000 and is registered in the Danish Business Register under CVR-/SE No. 25 88 14 35.

The product portfolio sets new norms for future treatment of cancer diseases with significant advantages for patients as well as the public health care system.

Meabco is currently following two paths; one path is the anti cancer therapeutic drug family (BP-C1) which in 3rd quarter will commence Clinical IIB or Clinical II/III trials.

The other path is the BP-C2, which is a drug for the prevention of side effects arising from cancer radiotherapy, nuclear radiation and irradiation at large.